Market Mover: Orasure (OSUR) Up at Midday May 13
Equities Staff Follow |Today Orasure Technologies Inc. (NASDAQ: OSUR) is trading 6.98% up.
The latest price, as of 12:04:34 est, was $5.49. Orasure has climbed $0.36 so far today.
174,344 shares have been traded today.
As of the previous close, Orasure has moved YTD 40.62%. The company is set to release earnings on 2022-08-03.
For technical charts, analysis, and more on Orasure visit the company profile.
About Orasure Technologies Inc.
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers.
To get more information on Orasure Technologies Inc. and to follow the company's latest updates, you can visit the company's profile page here: Orasure Technologies Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer